Novacell Technology develops novel biomarker that may accurately diagnose breast cancer

Published: 2013-08-22 06:57:00

Updated: 2013-08-22 06:57:00

Novacell Technology said yesterday it has created a new biomarker NCB102 that is considered to a highly accurate method of obtaining a preoperative histological diagnosis of breast cancer showing a resistance to Roche’s Herceptin.

Recently, the company conducted a clinical test in a local univ...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK